Insulet (NASDAQ:PODD) Stock Price Down 5% on Insider Selling

Key Points

• Insulet Corporation's stock price dropped 5% following insider selling by senior vice presidents Laetitia Cousin and Prem Singh, who reduced their holdings significantly.
• Despite the recent decline, analysts maintain a generally positive outlook on Insulet, with a consensus rating of "Moderate Buy" and a target price averaging $335.12.
• The company's second-quarter earnings reflected strong performance, with a reported earnings per share (EPS) of $1.17, surpassing estimates and indicating a year-over-year revenue increase of 32.9%.

Insulet Corporation (NASDAQ:PODD - Get Free Report) shares fell 5% during trading on Wednesday after an insider sold shares in the company. The stock traded as low as $330.00 and last traded at $335.01. 171,562 shares traded hands during mid-day trading, a decline of 77% from the average session volume of 747,968 shares. The stock had previously closed at $352.82.

Specifically, SVP Laetitia Cousin sold 797 shares of the stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the sale, the senior vice president directly owned 3,890 shares of the company's stock, valued at $1,356,870.90. This represents a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Prem Singh sold 687 shares of the company's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the sale, the senior vice president owned 3,456 shares of the company's stock, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their position. The disclosure for this sale can be found here.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on PODD. Wolfe Research upgraded shares of Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 price objective on the stock in a research note on Tuesday, May 13th. Jefferies Financial Group restated a "buy" rating on shares of Insulet in a research note on Thursday, August 7th. Morgan Stanley reiterated an "overweight" rating on shares of Insulet in a research note on Thursday, August 7th. Barclays raised their target price on shares of Insulet from $266.00 to $300.00 and gave the company an "equal weight" rating in a research note on Thursday, August 21st. Finally, Royal Bank Of Canada raised their price target on shares of Insulet from $330.00 to $350.00 and gave the stock an "outperform" rating in a research report on Friday, August 8th. Sixteen analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $335.12.

Insulet Stock Down 3.9%

The business's fifty day moving average price is $309.32 and its 200 day moving average price is $290.77. The company has a market capitalization of $23.86 billion, a P/E ratio of 102.69, a P/E/G ratio of 2.90 and a beta of 1.36. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm had revenue of $649.10 million during the quarter, compared to the consensus estimate of $612.31 million. During the same period last year, the firm posted $0.55 EPS. The firm's quarterly revenue was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, equities research analysts predict that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Insulet

Several institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in Insulet by 0.5% during the 2nd quarter. Vanguard Group Inc. now owns 8,708,355 shares of the medical instruments supplier's stock valued at $2,735,991,000 after purchasing an additional 39,403 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Insulet by 3.1% during the 2nd quarter. Geode Capital Management LLC now owns 1,927,543 shares of the medical instruments supplier's stock valued at $603,211,000 after purchasing an additional 58,309 shares during the last quarter. American Century Companies Inc. lifted its holdings in Insulet by 34.8% during the 1st quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier's stock valued at $302,686,000 after purchasing an additional 297,734 shares during the last quarter. Groupama Asset Managment lifted its holdings in Insulet by 0.4% during the 1st quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier's stock valued at $276,728,000 after purchasing an additional 3,759 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Insulet in the second quarter worth about $324,689,000.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.